Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact
Authors:
Open Access
- 21 November 2023
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 99 (2) , E51-E54
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (82270146, 81970117)
This publication has 14 references indexed in Scilit:
- Myelodysplastic SyndromesNew England Journal of Medicine, 2020
- Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesBlood Advances, 2020
- Treatment of MDSBlood, 2019
- European recommendations and quality assurance for cytogenomic analysis of haematological neoplasmsLeukemia, 2019
- Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)Blood Cancer Journal, 2017
- Characterization of TP53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotypeEuropean Journal of Haematology, 2017
- Targeted next‐generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS‐RAmerican Journal of Hematology, 2017
- Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromesLeukemia, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013